Working… Menu
Trial record 53 of 1543 for:    Androgens

Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00661492
Recruitment Status : Completed
First Posted : April 18, 2008
Results First Posted : December 9, 2016
Last Update Posted : December 9, 2016
ImClone LLC
Oregon Health and Science University
Information provided by (Responsible Party):
US Oncology Research

Brief Summary:
To determine the time to progression produced by the combination of Novantrone (mitoxantrone) and Erbitux (cetuximab) versus Novantrone alone in metastatic AIPC patients previously treated with docetaxel-based chemotherapy. TTP is defined as time from the start of treatment date to the date the patient is first recorded as having disease progression, even in patients who discontinue study treatment early due to toxicity.

Condition or disease Intervention/treatment Phase
Androgen-independent Prostate Cancer Drug: cetuximab Drug: Mitoxantrone Phase 2

Detailed Description:

This is a nonblinded, randomized phase II study to determine the activity of Novantrone (mitoxantrone) with or without Erbitux (cetuximab) in patients with androgen independent prostate cancer (AIPC) who have been treated previously with docetaxel chemotherapy. The Novantrone (mitoxantrone)-only treatment arm will serve as a concurrent control arm to aid in the determination of the benefit of the Novantrone (mitoxantrone)-Erbitux (cetuximab) combination in this setting.

Patients will be randomly assigned 2:1 to 1 of 2 treatment arms; 93 patients in Arm 1 and 47 patients in Arm 2. A balanced randomization procedure will be performed utilizing a code list that will be developed prior to the study opening. Because the patients will be stratified by performance status (ECOG 0 and 1 vs. ECOG 2), the list will be developed to ensure a balance between the 2 treatment arms.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 115 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Phase II Study of Mitoxantrone vs. Mitoxantrone With Cetuximab in Metastatic Androgen Independent Prostate Cancer (AIPC) Previously Treated With Docetaxel-based Chemotherapy
Study Start Date : May 2008
Actual Primary Completion Date : March 2011
Actual Study Completion Date : June 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: Arm 1
Erbitux (cetuximab) and Novantrone (mitoxantrone)
Drug: cetuximab
Erbitux (cetuximab) IV over 2 hours (loading dose) on Day 1 (Cycle 1 only), followed by Erbitux (cetuximab) IV over 1 hour weekly thereafter
Other Name: Erbitux

Drug: Mitoxantrone
Novantrone (mitoxantrone) IV Day 1 + Prednisone QD for ten (10) 21-day cycles Standard androgen deprivation therapy (ADT) will be continued in all patients who enter study on LHRH agonists
Other Name: Novantrone

Experimental: Arm 2
Novantrone (mitoxantrone)
Drug: Mitoxantrone
Novantrone (mitoxantrone) IV Day 1 + Prednisone QD for ten (10) 21-day cycles Standard androgen deprivation therapy (ADT) will be continued in all patients who enter study on LHRH agonists
Other Name: Novantrone

Primary Outcome Measures :
  1. Median Time to Progression (TTP) [ Time Frame: 24 months ]
    TTP will be measured from the start of treatment date to the date the patient is first recorded as having disease progression (even in patients who discontinue study treatment early due to toxicity or death due to disease progression.

Secondary Outcome Measures :
  1. 2-year Radiographically Evident Progression-free Survival (REPFS). [ Time Frame: 24 months. ]

    Radiographic progression:

    1) For bone scan, 2 unequivocal new lesions confirmed by a subsequent bone scan with at least 1 more new lesion; 2) Skeletal related event (eg, fracture, need for radiation to bone for pain, spinal cord compression, need for surgery to bone to prevent or treat a pathologic fracture).

  2. Objective Response Rate (ORR) [ Time Frame: 24 months ]
    ORR = CR + PR Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.

  3. Median Time to Prostate-specific Antigen (PSA) Progression [ Time Frame: 24 months ]
    Defined as the time from initiation of therapy until the first 25% increase from baseline in non-responders or 50% increase from nadir in responders as defined above. A minimum increase in the PSA of 5 ng/mL will be required for progression.

  4. Prostate-specific Antigen (PSA) Response Rate [ Time Frame: 24 months ]
    Defined as the fraction of patients with a ≥50% reduction in serum PSA confirmed by a second serum PSA at least 3 weeks later

  5. Prostate-specific Antigen (PSA) Doubling Time [ Time Frame: 24 months ]
    PSA doubling time = [log (2)× t] ÷ [log (final PSA) - log (initial PSA)]

  6. Median Progression-free Survival (PFS) [ Time Frame: 24 months ]
    PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date.

  7. Median Overall Survival (OS) [ Time Frame: 30 months ]
    OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed adenocarcinoma of the prostate. Note: Patients may have either measurable or non-measurable disease.
  • Radiographic evidence of regional or distant metastases
  • Current evidence of progression (by PSA and/or imaging studies) despite standard hormonal therapy.
  • Progression by PSA will be defined as: A rising PSA defined as: at least 2 rises in PSA over a reference value (PSA #1). The first rising PSA (PSA #2) must be taken at least 1 week after PSA #1. A third PSA (PSA #3) is required to be greater than PSA #2; if not, a fourth PSA (PSA #4) is required to be greater than PSA #2. Progression for nonmeasurable disease will be defined as 2 or more new bone lesions; for measurable disease, progression will be defined by standard RECIST criteria.
  • For patients who have been on antiandrogen therapy (ie, bicalutamide, flutamide, etc.), patients must have discontinued anti-androgen therapy for at least 6 weeks (4 weeks for flutamide) without evidence of an antiandrogen withdrawal response. A washout period will not be required for patients who did not respond to an antiandrogen prescribed as second line hormonal therapy. For patients whose progression is documented by PSA, the last required PSA must be after the required anti-androgen washout period (4-6 weeks as appropriate).
  • One prior docetaxel-containing regimen. Patients must have received at least 2 doses in an every 3-week schedule or 6 doses on a weekly schedule of docetaxel. Patients may have discontinued therapy due to progression, intolerance, completion of planned therapy, or other reasons. Chemotherapy treatment with any second-line regimen will not be permitted. Patients who have been previously treated with a first-line docetaxel-based doublet regimen will be eligible for this study, (eg, patients treated on a prior first-line trial containing a docetaxel/carboplatin or other docetaxel-based doublet).
  • Serum testosterone levels (See protocol for specific details) (unless surgically castrate). Patients must continue androgen deprivation with an LHRH agonist if they have not undergone orchiectomy
  • ECOG performance status
  • Laboratory criteria for entry:

    • absolute neutrophil count
    • platelets
    • bilirubin
    • AST or ALT
  • Life expectancy greater than 3 months
  • Age greater than or equal to 18 years
  • Agree to use contraceptives while on study if sexually active, and for 2 months after the last dose of study drug.
  • Has signed a Patient Informed Consent Form
  • Has signed a Patient Authorization Form

Exclusion Criteria:

  • More than 1 prior chemotherapy regimen for metastatic disease
  • Prior history of uncontrolled congestive heart failure or left ventricular ejection fraction (LVEF) that is less than the institution's lower limit of normal on MUGA or echocardiogram
  • A second active malignancy (diagnosed within 5 years) except adequately treated non-melanoma skin cancer or other non-invasive or in-situ neoplasm
  • Significant active concurrent medical illness or infection
  • Treatment with chemotherapy for AIPC within the past 21 days
  • Prior treatment with Novantrone (mitoxantrone)
  • Prior therapy which specifically and directly targets the EGFR pathway
  • Prior severe infusion reaction to a monoclonal antibody
  • Recent myocardial infarction (within prior 6 months)
  • Prior treatment with radionuclides, with the exception of prior treatment with samarium, which will be allowed provided at least 8 weeks have passed since administration.
  • Is receiving concurrent immunotherapy, hormonal therapy, radiation therapy, or any other non-protocol therapy (excluding LHRH antagonist)
  • Is receiving concurrent investigational therapy or has received such therapy within the past 30 days
  • Has evidence of CNS involvement
  • Has a serious uncontrolled intercurrent medical or psychiatric illness, including serious infection.
  • Is unable to comply with requirements of study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00661492

  Show 55 Study Locations
Sponsors and Collaborators
US Oncology Research
ImClone LLC
Oregon Health and Science University
Layout table for investigator information
Principal Investigator: Mark T. Fleming, MD Virginia Oncology Associates/US Oncology

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: US Oncology Research Identifier: NCT00661492     History of Changes
Other Study ID Numbers: 06-118
First Posted: April 18, 2008    Key Record Dates
Results First Posted: December 9, 2016
Last Update Posted: December 9, 2016
Last Verified: October 2016
Keywords provided by US Oncology Research:
Androgen-independent prostate cancer(AIPC)
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Molecular Mechanisms of Pharmacological Action
Sensory System Agents
Peripheral Nervous System Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors